	1a. Inclusion/exclusion criteria	1b. Demographic characteristics	1c. Recruitment procedure	2a. Standardization of somatosensory assessment	2b. Method of somatosensory assessment	3. Handling of confounders
Amatya et al., 2010	?	•	•	?	•	•
Andersen et al., 2017	•	•	•	•	•	•
Bin Saif et al., 2013	•	•	•	?	•	?
Falcone et al., 2017	?	•	•	?	•	•
Gronroos et al., 1997	•	?	•	?	•	•
Hawro et al., 2014	•	•	•	?	•	?
Hawro et al., 2016	•	•	•	?	•	•
Heyer et al., 1989	•	•	•	?	•	•
Heyer et al., 1991	•	•	?	?	?	•
Heyer et al., 1995	•	•	•	?	•	•
Heyer et al., 1997	•	?	•	?	•	•
Heyer et al., 1998	?	•	•	?	•	•
Hosogi et al., 2006	•	•	•	?	•	•
Ikoma et al., 2003	?	•	•	?	•	?
Ikoma et al., 2004	?	•	•	?	•	?
Ikoma et al., 2005	•	•	•	?	•	•
Ishiuji et al., 2008	•	?	•	?	•	?
Ishiuji et al., 2009	•	•	•	?	•	•
Kobayashi et al., 2003	•	•	•	?	?	•
Koppert et al., 1996	•	•	•	?	•	?
Krzanowska et al., 2015	•	•	•	?	•	?
Mochizuki et al., 2015	_	•	_	?	•	?
Mori et al., 2010	•	•	•	?	•	?
Nattkemper et al., 2015	_	•	•	?	•	•
Neisius et al., 2002	•	•	•	?	•	?
Ozawa et al., 2009	_	•	•	?	•	?
Papoiu et al., 2011	•	•	•	?	•	?
Pereira et al., 2017	•	•	•	•	•	?
Rasul et al., 2013	•	•	•	?	•	•
Rukwied and Heyer, 1998	•	•)	?	•	•
Rukwied and Heyer, 1999 Rukwied et al., 2000	•	•	_	?	•	?
Schneider et al., 2008	•	•	•	?	•	?
Schneider et al., 2008	•	•	_	•	•	?
Steinhoff et al., 2003	•		_	?	•	•
Tey et al., 2016	•	•) (?	•	•
Tran et al., 2010	•	•)	?	•	•
Van Laarhoven et al., 2007		•	•	?	•	?
Van Laarhoven et al., 2010		•	•	?	•	?
Van Laarhoven et al., 2016	•	•	•	?	•	?
Vogelsang et al., 1995	•	•		?	•	•
Wahlgren and Ekblom, 1996	?	•	•	?	•	?
Wahlgren et al., 1990	•	•	•	?	•	?
Wahlgren et al., 1995	•	•	•	?	•	?
Weisshaar et al., 1998	•	•	•	?	•	•
Yudina et al., 2011	•	•	•	?	•	•
	_				_	

Supplementary Fig. 1 Risk of bias graph: review authors' judgments about each risk of bias item for each included study. Green = 'low' risk of bias; Yellow = 'unclear' risk of bias; Red = 'high' risk of bias.

	Patients	s (non-lesi	onal)	Heal	thy contr	ols		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 AD									
Andersen et al., 2017	33.5	24.9	25	37.5	25.1	25	10.5%	-0.16 [-0.71, 0.40]	
Hawro et al., 2016	29.32	18.256	22	33.5	16.089	18	10.1%	-0.24 [-0.86, 0.39]	
lkoma et al., 2003	1.5	1.27	18	3.1	0.775	15	9.0%	-1.45 [-2.23, -0.67]	
Ishiuji et al., 2008	32	25	16	22	12	10	8.8%	0.46 [-0.34, 1.26]	+
Rasul et al., 2013	26.7	22.1	25	39	26.6	25	10.5%	-0.50 [-1.06, 0.07]	
Rukwied et al., 2000	1.99	0.26	9	2.9	0.16	9	4.1%	-4.01 [-5.76, -2.27]	
Schneider et al., 2008	8	1.77	8	8	1.1	6	7.2%	0.00 [-1.06, 1.06]	
Wahlgren and Ekblom, 1996	43.4	23.4	20	31	25.6	20	10.0%	0.50 [-0.13, 1.13]	 -
Wahlgren et al., 1990	49.7	30.1	32	42.7	28.3	32	10.9%	0.24 [-0.26, 0.73]	_ -
Subtotal (95% CI)			175			160	81.1%	-0.36 [-0.88, 0.17]	•
Heterogeneity: Tau ² = 0.48; Chi	² = 39.65,	df=8 (P <	0.00001); $I^2 = 80$	0%				
Test for overall effect: Z = 1.33 (P = 0.18)								
1.2.2 PSO									
Amatya et al., 2010	19.4	28.4	15	28.8	24.2	15	9.4%	-0.35 [-1.07, 0.38]	
Subtotal (95% CI)			15			15	9.4%	-0.35 [-1.07, 0.38]	◆
Heterogeneity: Not applicable									
Test for overall effect: $Z = 0.94$ (P = 0.35)								
1.2.3 CCCA									
Bin Saif et al., 2013	5.13	2.7	16	4.8	2.48	15	9.5%	0.12 [-0.58, 0.83]	
Subtotal (95% CI)			16			15	9.5%	0.12 [-0.58, 0.83]	•
Heterogeneity: Not applicable									
Test for overall effect: $Z = 0.34$ (P = 0.73)								
Total (95% CI)			206			190	100.0%	-0.29 [-0.72, 0.14]	•
Heterogeneity: Tau ² = 0.37; Chi	² = 40 54	df = 10 (P :): IP = 74	596			3.20 [3.12, 3111]	
Test for overall effect: Z = 1.33 (ui - 10 (1	. 5.0001	7. i = 1.	J 70				-4 -2 0 2 4
Test for subgroup differences:		Af = 2 /D	- 0.62\	IZ — ∩04					Patients less sensitive Patients more sensitive
restroi subdroup unierefices.	ont - 1.28	o, ui – 2 (F	- 0.52),	1 - 070					

Supplementary Fig. 2 Forest plot of the random effects meta-analysis for the outcome peak itch during histamine provocations on non-lesional skin of patients and healthy controls. *Abb reviations: AD: Atopic Dermatitis; CCCA: Central centrifugal cicatricial Alopecia; CI = confidence interval; PSO: Psoriasis; SD: Standard deviation; Std.: standardized*

	Patient	ts (lesio	nal)	Health	ny conti	rols		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
2.2.1 AD									
Andersen et al., 2017	57	28.8	25	37.5	25.1	25	22.0%	0.71 [0.14, 1.28]	-
Ikoma et al., 2003	4.4	1.3	18	3.1	0.8	15	19.9%	1.15 [0.40, 1.90]	_ -
Ishiuji et al., 2008	69	34	16	22	12	10	17.6%	1.63 [0.71, 2.56]	
Subtotal (95% CI)			59			50	59.5%	1.07 [0.56, 1.57]	•
Heterogeneity: Tau² = 0	.07; Chi ² =	= 2.92, d	lf=2 (P	= 0.23);	$I^2 = 32^9$	%			
Test for overall effect: Z	= 4.11 (P	< 0.000	1)						
2.2.2 PSO									
Amatya et al., 2010	17.9	31.6	15	28.8	24.2	15	20.2%	-0.38 [-1.10, 0.35]	
Subtotal (95% CI)			15			15	20.2%	-0.38 [-1.10, 0.35]	—
Heterogeneity: Not appl	licable								
Test for overall effect: Z	= 1.02 (P	= 0.31)							
2.2.3 CCCA									
Bin Saif et al., 2013	1.69	1.74	16	1.93	2.74	15	20.4%	-0.10 [-0.81, 0.60]	
Subtotal (95% CI)			16			15	20.4%	-0.10 [-0.81, 0.60]	—
Heterogeneity: Not appl									
Test for overall effect: Z	= 0.29 (P	= 0.78)							
Total (95% CI)			90			80	100.0%	0.58 [-0.10, 1.25]	
	40: 01:3	47.00			41.19		100.070	0.56 [-0.10, 1.25]	
Heterogeneity: Tau ² = 0			ai = 4 (P = 0.00	1); 1*= .	1170			-4 -2 0 2 4
Test for overall effect: Z	•		00 46	2.00	0000 13		01		Patients less sensitive Patients more sensitive
Test for subgroup differ	ences: Ch	117= 13.	υυ, ατ =	Z(P=0)	.002), l*	= 84.6	70		

Supplementary Fig. 3 Forest plot of the random effects meta-analysis for the outcome peak itch during histamine provocations on lesional skin of patients and healthy controls. *Abb reviations: AD: Atopic Dermatitis; CCCA: Central centrifugal cicatricial Alopecia; CI = confidence interval; PSO: Psoriasis; SD: Standard deviation; Std.: standardized*



PRISMA 2009 Checklist

Supplementary Table 1 PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Suppl. Table 2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	5-6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5-6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., 1^2) for each meta-analysis.	6

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	6
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-10, Fig 3-6, Suppl. Fig 2, 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8-10, Fig 3-6, Suppl. Fig 2, 3
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	7, Fig. 2, Suppl. Fig. 1
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	n.a.
DISCUSSION	-		
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	11-14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	11-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	11-14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	14

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Review's and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

 $\textbf{Supplementary} \quad \textbf{Table 2} \ \ \text{MeSH terms and Boolean operators used in the Pubmed search (comparable terms, e.g., MeSH and EMTREE, were used for the databases Embase and the Cochrane Library).$

Search strategy in Pubmed

search shalegy in	Ludiku
1.	Pruritus [MeSH] OR
	Atopic dermatitis [MeSH] OR
	Psoriasis [MeSH] OR
	Urticarial [MeSH] OR
	Neuropathicitch [MeSH]
2.	chronic prurit* [Title/Abstract] OR
	chronicitch* [Title/Abstract] OR
	atopic dermatit* [Title/Abstract] OR
	atopic eczem* [Title/Abstract] OR
	psoriasis [Title/Abstract] OR
	urticarial [Title/Abstract] OR
	neuropathicitch* [Title/Abstract] OR
3.	OR/1,2
4.	quantitative sensory testing [Title/Abstract] OR
	QST [Title/Abstract] OR
	stimuli* [Title/Abstract] OR
	acetylcholin* [Title/Abstract] OR
	BAM-22 [Title/Abstract] OR
	BAM22 [Title/Abstract] OR
	beta-alanin* [Title/Abstract] OR
	bradykinin* [Title/Abstract] OR
	capsaicin* [Title/Abstract] OR
	chemic* [Title/Abstract] OR
	codein* [Title/Abstract] OR
	compound 48* [Title/Abstract] OR
	cowag* [Title/Abstract] OR
	cowhag* [Title/Abstract] OR
	electric* [Title/Abstract] OR
	frey [Title/Abstract] OR
	histamin* [Title/Abstract] OR
	interleukin* [Title/Abstract] OR
	mechanic* [Title/Abstract] OR
	monofilament* [Title/Abstract] OR
	mucuna prur* [Title/Abstract] OR
	PAR2 [Title/Abstract] OR
	PAR-2 [Title/Abstract] OR
	prostagland* [Title/Abstract] OR
	SLIGR* [Title/Abstract] OR
	substance P [Title/Abstract] OR
	tryptas* [Title/Abstract]
5.	itch* [Title/Abstract] OR
	prurit*[Title/Abstract]
6.	AND/3-5
7.	Animals [MeSH]
	NOT humans [MeSH]
8.	6/NOT 7